Daniel J. Williamson
Senior Manager at Iksuda Therapeutics focussed on developing the next generation of antibody-drug conjugates for the treatment of cancer and broader based therapeutics
Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety.
